cagA Status and Eradication Treatment Outcome of Anti-Helicobacter pylori Triple Therapies in Patients with Nonulcer Dyspepsia

AUTOR(ES)

Broutet, Nathalie

FONTE

American Society for Microbiology

RESUMO

The differences in eradication rates reported in clinical trials aiming to cure Helicobacter pylori infection cannot be entirely explained by the type of regimen, bacterial resistance, or lack of compliance. Using data from a clinical trial, a logistic regression model was constructed to determine whether cagA status, assessed by PCR, affects the outcome of eradication. Resistance to clarithromycin (10% of the strains) predicted failure perfectly. In the model (n = 156), a cagA-lacking strain (odds ratio [OR] = 2.2; 95% confidence interval [CI], (1.1 to 4.7), tobacco smoking OR = 3.1; 95% CI, 1.3 to 7.0), and a double dose of proton pump inhibitor in the treatment regimen (OR = 0.3; 95% CI, 0.2 to 0.7) were associated with the treatment outcome. The exact role of cagA in the outcome of H. pylori eradication therapy has not been explored. However, the type of histological lesions which it causes in the gastric mucosa may be implicated. Regardless of the mechanism involved, cagA status is a good predictive marker of eradication outcome.

Documentos Relacionados

• Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
• The effect of CagA status on response to Helicobacter pylori eradication therapy in Western Turkey
• cagA and vacA in strains of Helicobacter pylori from ulcer and non-ulcerative dyspepsia patients
• Anti-Helicobacter pylori and Anti-inflammatory Properties of Eugenia uniflora L.
• cagA and vacA Status of Spanish Helicobacter pylori Clinical Isolates